Skyrizi induction therapy bests placebo in refractory Crohn’s

Skyrizi induction therapy bests placebo in refractory Crohn’s

Crohn’s disease previously unresponsive to conventional and biologic therapies showed response to Skyrizi, achieving clinical remission in more than a third of patients regardless of dosing, according to a presentation at Digestive Diseases Week.“In ADVANCE and MOTIVATE, significantly more patients achieved the co-primary endpoints of clinical remission – with different definitions – and endoscopic response with risankizumab vs. placebo at week 12,” Geert R. D’Haens, MD, from Amsterdam University Medical Center said in his presentation. “RisankizumabRead More

Share on facebook
Share on twitter
Share on linkedin